Hemolytic uremic syndrome (HUS) is one of the disease processes that belong to thrombotic microangiopathies (TMAs). The common features for TMAs are microangiopathic hemolysis, thrombocytopenia, and thrombi in small vessels that lead to end organ damage. The most frequently encountered TMAs clinically are HUS associated with Shiga toxin–producing Escherichia coli (STEC) infection, as atypical HUS (aHUS), usually caused by uncontrolled complement activation, or as secondary HUS with a coexisting disease. In recent years, a general understanding of the pathogenetic mechanisms driving HUS has increased. Typical HUS (ie, STEC-HUS) follows a gastrointestinal infection with STEC, whereas aHUS is associated primarily with mutations or autoantibodies leading to dysregulated complement activation. Among the 30% to 50% of patients with HUS who have no detectable complement defect, some have either impaired diacylglycerol kinase ε (DGKε) activity, covalamin C deficiency, or plasminogen deficiency. Some have secondary HUS with a coexisting disease or trigger such as autoimmunity, transplantation, cancer, infection, certain cytotoxic drugs, or pregnancy. The common pathogenetic features in STEC-HUS, aHUS, and secondary HUS are simultaneous damage to endothelial cells, intravascular hemolysis, and activation of platelets leading to a procoagulative state, formation of microthrombi, and tissue damage. In this review, the differences and similarities in the pathogenesis of STEC-HUS, aHUS, and secondary HUS are discussed. Common for the pathogenesis seems to be the vicious cycle of complement activation, endothelial cell damage, platelet activation, and thrombosis. This process can be stopped by therapeutic complement inhibition in most patients with aHUS, but usually not those with a DGKε mutation, and some patients with STEC-HUS or secondary HUS. Therefore, understanding the pathogenesis of the different forms of HUS may prove helpful in clinical practice. (Blood. 2017; 129(21):2847-2856)

Initiation of disease processes in HUS

STEC-HUS

The process of pathogenesis in typical HUS or STEC-HUS is apparently initiated when the Shiga toxin (or Shiga-like toxin), a known potent cytotoxin, binds to cell membrane glycolipid Gb3 (via domain B). Domain A is internalized and subsequently halts protein synthesis and induces apoptosis of the affected cell. The Shiga toxin has several additional effects on endothelial cells, one of which is enhanced expression of functional tissue factor that could contribute to microvascular thrombosis. The toxin causes damage to or activation
of endothelium, red cells, and platelets. Clinically, STEC-HUS can be nearly as severe as aHUS (with mortality of up to 5%), as exemplified during the wide outbreak in Germany and some other European countries in 2011. The main reason why gastrointestinal infection particularly affects kidneys is thought to be the tissue tropism of Shiga-toxin on the basis of the strong expression of Gb3 on the glomerular endothelium.

**Secondary HUS**

Secondary HUS is initiated by a coexisting disease or condition. The most frequently reported diseases that lead to clinically evident secondary HUS include infections, especially those caused by *Streptococcus pneumoniae*, and the influenza virus. These infections are considered as causes of HUS not just triggers for the disease, although the distinction between cause and trigger is not evident. In addition to infections, secondary HUS may be associated with transplantation (solid organ or bone marrow), autoimmune disease, cancer, pregnancy, and the use of certain cytotoxic drugs. The common feature for these coexisting diseases or conditions is that they may cause direct cell damage, promote activation of the complement system in general, or enhance activation of complement on self cells (Figure 1).

**aHUS**

According to the currently prevailing classification, aHUS is not associated with infections or a coexisting disease. Instead, it is usually associated with a genetic or acquired defect in regulation of complement activation on host cells. In a number of aHUS patients, an infection (often an upper respiratory tract infection) precedes the clinical triad typical for TMAs. In aHUS, infections are usually considered as triggers, not as causes of the disease as such.

**Common features**

The symptoms and clinical signs may be practically identical in STEC-HUS, secondary HUS, and aHUS. Another common feature is that some patients with aHUS and also STEC-HUS and secondary HUS have either mutations or autoantibodies that are associated with impaired complement regulation. It is also noteworthy that the same set of cells (endothelial cells, red cells, and platelets) may be damaged or activated in both STEC-HUS and aHUS. The net result of all the activation and regulation boosting or inhibiting effects may dictate whether activation overrides regulation leading or contributing to a pathological process.

**Complement as a danger for plasma-exposed cells**

Complement is activated via 3 pathways: classical, lectin, and alternative. All the pathways lead to target elimination via 2 main mechanisms, which are phagocytosis and direct lysis. The more important of these is promotion of phagocytosis via opsonization with C3b and its fragments, as well as phagocyte attraction via release of powerful chemotactic and anaphylatoxic peptides such as C5a. These phenomena lead to rapid opsonophagocytosis of the target by neutrophils and macrophages (Figure 2A). The second main mechanism of target elimination by complement is direct lysis of target cells.
cells via formation of membrane pores, or so-called membrane attack complexes (Figure 2A).\textsuperscript{43,44} In addition to these effects, complement also has a role in initiating and enhancing the adaptive immunity.\textsuperscript{45}

**Activation of complement**

Most immune systems recognize targets by self molecules that bind to pathogen-associated molecular patterns (cellular immunity) or molecules specific to a certain microbe (antibody-mediated immunity). This is also true for the classical pathway of complement, which recognizes targets via binding of C1q to immunoglobulin G or M, and the lectin pathway, which recognizes glycans on the target surface via mannose-binding lectin or ficolins. Distinct from these is the alternative pathway of complement, which is based on constant and spontaneous low-level activation in plasma. This results in a low number of covalently bound (via hydroxyl or amine groups) C3b deposits onto practically all surfaces in contact with plasma. If the C3b molecule is allowed to form an enzyme (shown in red), new C3b deposits will be formed around the enzyme leading to rapid amplification of the activation. If the regulator factor H binds to C3b, the convertase enzyme is inactivated and no complement activation follows. The simultaneous interaction of factor H with both C3b and cell surface sialic acids (or possibly glycosaminoglycans [GAGs]) is essential for proper regulation on self red cells, platelets, and endothelial cells. If this fails, disbalance between activation and regulation may lead to pathogenesis of atypical HUS. iC3b, C3b molecule incapable of forming an enzyme with factor B.

The special feature of the alternative pathway to spontaneously attack any surface provides a strategy to defend against any kind of biomaterial. This feature, however, leads to a potential to attack host cells because some C3b is deposited onto self cells, too.\textsuperscript{49} Therefore, all cells in contact with plasma without proper defenses are at risk of destruction, making continuous and efficient downregulation of complement essential to self cells. If the regulation on host cells is compromised, as is often seen in aHUS and occasionally in other forms of HUS, the amplified attack may rapidly cause cell and tissue damage.

**Regulation of complement**

The main complement regulators are the plasma protein factors H and I and the membrane proteins CD35, CD46, CD55, and CD59.\textsuperscript{50} Four of the control proteins, factor H, CD35, CD46, and CD55, control C3b on cell surfaces by acting as cofactors for factor I in proteolytic inactivation of C3b, competing with factor B in binding to C3b, accelerating decay of the formed C3bBb enzyme, or by a mixture of these effects.\textsuperscript{51} These proteins all contribute to the protection of endothelial cells; red blood cells lack CD46\textsuperscript{52} and platelets lack CD35.\textsuperscript{53,54} CD59 acts later in the cascade by blocking assembly of the lytic membrane attack complex on all plasma-exposed cells.

Studies on the pathogenesis of aHUS have revealed a central role of factor H in discriminating between self cells and microbes (ie, whether a target should be spared or destroyed).\textsuperscript{55,56} If factor H binds to C3b deposited onto a surface, activation is efficiently inhibited. In the
Complement may cause cell damage in HUS

Mutations in complement proteins in aHUS

In STEC-HUS and secondary HUS, the disease process is usually initiated by phenomena distinct from the complement system or linked only indirectly to complement activation. In aHUS, however, complement is centrally involved. In aHUS, mutations have been reported in 5 central complement proteins. Most of these mutations lead to impaired regulation of alternative pathway activation. Some disturb recognition of C3b by factor H,56,60 factor I,61 or CD46;62 some disturb recognition of self-cell surface molecules, such as sialic acid or glycosaminoglycans, by factor H.55,59 Some mutations in C3 or factor B gain of complement activation.63,64 The frequencies of mutations observed in aHUS are shown in Table 1. In addition, autoantibodies against factor H can interfere with regulation in a manner similar to mutations.69 The common feature for the mutations and autoantibodies is impaired control of the complement alternative pathway on self-cell surfaces.

Complement-mediated red cell and endothelial damage in HUS

Cells that are continuously exposed to complement alternative pathway activation include all cells in contact with plasma: red cells, platelets, leukocytes, and endothelial cells. The most vulnerable to rapid lysis seem to be red cells, because they lack an efficient membrane repair system as observed in nucleated cells. However, some shedding of the complement membrane attack complexes on these cells can occur,70 but contribution of this phenomenon to the protection of red cells from complement lysis has not been proven. Complement attack against red cells can rapidly lead to release of hemoglobin, as seen in paroxysmal nocturnal hemoglobinuria (PNH).71 There are two main mechanistic explanations underlying hemolysis and the appearance of red cell fragments and schistocytes in the peripheral blood in aHUS (i.e., signs of microangiopathic hemolysis characteristic for TMAs).72,73 The first and traditional explanation is mechanical hemolysis as a result of narrowed microvasculature caused by microthrombi. However, narrowed capillaries have not been experimentally proven to lead to hemolysis or schistocytes in HUS. One of the main problems with this explanation is that deformability of normal red cells is high, and channels narrower than 3 μm in diameter do not allow passage of red cells at all.74 The second explanation, complement-mediated lysis, is also possible either as a primary or secondary cause, but the main challenge in this explanation is that red cell fragments and schistocytes are not typical for complement-mediated lysis in PNH.75 Thus, there may be alternative mechanisms linked to stiffening of the red cell membrane by complement C3d (or factor B) deposits.76,77 Further studies are needed to clarify the mechanism for the clinically characteristic hemolysis in HUS cases associated with complement regulation defects.

Endothelial cells and leukocytes can remove complement deposits and membrane attack complexes more efficiently than red cells, either by internalization or by shedding from the plasma membrane in microvesicles.78,79 In addition, these cells may also repair membrane damage. Endothelial cell damage is evident in histologic analysis of biopsies taken from HUS patients during the acute stage.80 The reason for endothelial cell damage in STEC-HUS is linked to Shiga toxin, whereas damage in aHUS has been attributed to lytic or sublytic complement attack.81,82 However, several other mechanisms affecting endothelial cells can cause or contribute to the damage. Examples of such factors are cell exposure to nitric oxide, free hemoglobin, activated neutrophils and monocytes or released reactive oxygen species from these cells, C3a or C5a, proinflammatory cytokines, proinflammatory or procoagulant microparticles, or cellular hypoxia due to microthrombi.

Cell damage–induced complement activation in HUS

Independent of the reason for the damage, injured endothelium may activate the complement cascade.82 This activation may occur not only via the alternative pathway but also (as observed in ischemia reperfusion injury) by the classical and lectin pathways via exposure of novel epitopes recognized by these pathways.83 In aHUS, the alternative pathway is likely to be responsible for the damage, because the disease is associated with dysregulation of this pathway in particular.8 The damage-induced enhancement of complement activation can lead to further damage of nearby cells, both the cells residing in the immediate area and those passing by in the vicinity.84 It has long been assumed that damage to endothelial cells is the first step in

<table>
<thead>
<tr>
<th>Mutated gene/protein</th>
<th>Type</th>
<th>Frequency (%)*</th>
<th>Death or end-stage renal disease 3-10 y after onset (%)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor H (including CFH/CFHR1 hybrid genes)</td>
<td>Loss of complement regulation</td>
<td>24-28</td>
<td>70-80</td>
</tr>
<tr>
<td>MCP (CD46)</td>
<td>Loss of complement regulation</td>
<td>5-9‡</td>
<td>&lt;20</td>
</tr>
<tr>
<td>Factor I</td>
<td>Loss of complement regulation</td>
<td>4-8</td>
<td>60-70</td>
</tr>
<tr>
<td>C3</td>
<td>Gain of complement activation</td>
<td>2-8</td>
<td>60-70</td>
</tr>
<tr>
<td>Factor B</td>
<td>Gain of complement activation</td>
<td>0-4</td>
<td>70</td>
</tr>
<tr>
<td>Thrombomodulin</td>
<td>Possibly loss of complement regulation and procoagulative state</td>
<td>0-5</td>
<td>50-60</td>
</tr>
<tr>
<td>CFHR1/3 deficiency with anti-factor H autoantibodies</td>
<td>Loss of complement regulation</td>
<td>3-10§</td>
<td>30-70</td>
</tr>
<tr>
<td>Diacylglycerol kinase ε</td>
<td>Prothrombotic</td>
<td>0-3†</td>
<td>46</td>
</tr>
<tr>
<td>None identified</td>
<td></td>
<td>30-48</td>
<td>50</td>
</tr>
</tbody>
</table>

*Frequencies of the genetic abnormalities have been adopted from a recent review6 and cohort studies.65,66†The values represent averages of the earlier reported values.10,30,65-67§Frequency of the isolated heterozygous MCP (CD46) mutation is usually 7% to 8%, but the mutations are frequently found in combination with other mutations in complement genes (up to 22%).57 When considering autoantibodies against factor H, 56% of pediatric aHUS cases in India.49 | 58,59| 60-70 | 70-80 | 4-8 | 2-8 | 0-4 | 0-5 | 3-10§ | 0-3† | 30-48 | 50 |
Platelets and coagulation in the pathogenesis of HUS

Platelets in the pathogenesis of aHUS

Complement-mediated platelet activation has gained much less attention in aHUS than hemolysis or endothelial cell damage. Platelets may, however, be involved, either primarily or secondarily, in pathogenesis of this disease because thrombocytopenia is a typical feature of TMA,90 and the thrombi in capillaries and arterioles contain platelets91 in addition to red cells.91 Platelets are easily activated by complement attack92 via the formation of membrane attack complex on the platelet membrane,93 but some internalization or shedding of these cells compared with that of endothelial cells is possible although not proven.94

Links between complement, coagulation, and platelets in HUS

The common conclusion from the numerous studies linking complement and coagulation is that complement activation leads to initiation or enhancement of coagulation. Complement can trigger coagulation by 2 primary means. First, complement causes tissue damage via formation of membrane attack complexes on endothelial cells. Second, complement activation leads to release of C5a or formation of soluble C5b-9 complexes that can induce endothelial cell activation and expression of procoagulative tissue factor.95-97 In addition, numerous molecular interactions between complement and coagulation proteins have been described.98,99 The physiological relevance of most of these interactions has not been proven. Some interactions, such as cleavage of C5 by thrombin, may be clinically relevant.100,101

There are also links between complement and platelets. The most important of these seems to be the activation of platelets by membrane attack complexes92 or C5a.102 The procoagulative effect of membrane attack complexes seems to be mediated by platelet prothrombinase,103 not by irreversible cell damage.104 Independent of the reason for the activation of platelets, it is well known that their activation and aggregation is closely linked to coagulation, thereby creating another bridge between activation of the complement and coagulation cascades. In the pathogenesis of all 3 forms of HUS, formation of microthrombi in capillaries and arterioles is central. The most important links between complement activation, coagulation, and platelets in HUS are shown in Figure 3.

Complement in disease processes and therapy of HUS

Infections and complement activation

There are several reasons why infections are associated with HUS in general: direct cell or tissue damage caused by a microbe, as seen in STEC-HUS; indirect damage caused by complement activation promoted by the pathogen,105; infection-associated autoantibody formation against factor H106; or possibly coagulation disorders during infection.24 The acute phase reaction may also contribute, because several complement proteins (at least C3, C1s, factor B, C5, C4, and C1q107,108) are acute phase reactants. This provides an explanation for the observed increase in complement hemolytic activity during the acute phase.109 Increased plasma concentrations of these proteins do not trigger complement activation as such but could promote activation upon complement-activating circumstances caused by the microbe itself or damaged host tissues.

Our recent study provided a novel possible explanation for why certain infections can lead to secondary HUS. We observed that sialic acid in in vitro assays is the main ligand for factor H on red cells and also on platelets and endothelial cells.25 Pneumococci22 and influenza A virus,24 most often seen in secondary HUS associated with infections, possess very active neuraminidases specialized in removing sialic
Continuation of disease after removing the trigger

The course of STEC-HUS is usually self-limiting, although acute kidney injury and systemic involvement can complicate and prolong the disease. On the contrary, in some patients with aHUS, or sometimes secondary HUS, the acute disease continues after the trigger has been removed. This is especially striking in patients who have a mutation in a complement regulatory molecule for decades without symptoms but fail to control the disease even several months after it has been triggered. All the provided explanations for this phenomenon are controversial. One explanation is that complement attack against self cells during the acute disease flare leads to damage-induced amplification of 1 or more of the pathways, providing potential for longstanding complement activation. This is demonstrated by slow normalization of early complement activation markers such as C3 fragments or factor B only after several months of C5-blocking eculizumab therapy. Most patients do not experience a relapse upon discontinuation of therapeutic complement inhibition, although patients with factor H mutations often do. Another explanation for the longstanding disease process is that endothelial cell activation continues for months after the rapid termination of hemolysis and increase in platelet count.

Therapeutic complement inhibition provides insight into pathogenesis of HUS

The impact of complement activation on the pathogenesis of STEC-HUS, aHUS, and secondary HUS seems to be variable, apparently because of the biological phenomena linked to the pathogenesis. The impact of complement is seen most clearly in observing the effects of therapeutic complement inhibition on these diseases. As expected, complement inhibition is effective in patients who have a mutation in complement molecules or autoantibodies against factor H. The efficacy of therapeutic complement inhibition in patients with secondary HUS has not been systematically assessed, but it has been shown to be beneficial in a number of patients who do not have a mutation in any of the studied complement proteins. These include patients with autoimmunity (eg, scleroderma), systemic lupus erythematosus, or catastrophic antiphospholipid syndrome and secondary HUS associated with postpartum period. HIV infection, use of cytotoxic drugs, and either bone marrow or solid organ transplantation. On the basis of these multiple single cases, it seems that complement is involved in at least some patients with secondary HUS. There is currently insufficient evidence to classify secondary HUS into complement-driven and complement-independent forms, but this might become a clinically relevant subclassification of secondary HUS in the future, as hinted at by some diagnostic algorithms. From a clinical point of view, it already is important and will probably be even more important in the future for making justified decisions regarding which secondary HUS patients will need expensive therapeutic complement inhibitors.

Although complement clearly contributes to disease pathogenesis in some patients with STEC-HUS, and some patients seem to benefit from early administration of eculizumab, most STEC-HUS patients do not respond clearly to this drug. TTP is also not generally considered to be an indication for eculizumab treatment mainly because plasma therapy is usually effective. Despite this, eculizumab has been beneficial in some TTP cases that are refractory to conventional therapy. Eculizumab does not seem to be effective for the aHUS patients in whom a DGKε mutation is found or in those with cobalamin C deficiency in adulthood; however, this treatment has been attempted in only a limited number of patients.
Multiple parallel processes leading to clinically significant tissue damage

**Parallel processes in pathogenesis of aHUS**

The cellular or molecular consequences discussed above can be summarized as parallel or consecutive phenomena with regard to the various cells involved and the clinical signs typical for HUS and aHUS, thereby forming a model of HUS pathogenesis (Figure 4). In this model, the process is not linear but cyclical, and possibly all the processes happen simultaneously in vivo. However, such a process may be initiated from different stages, resulting in a similar vicious cycle. The primary point of process initiation could be in complement-mediated cell damage, direct activation of platelets, initiation of a procoagulative state in the endothelium, dysregulation of the coagulation or thrombotic pathways, or direct complement-independent cell damage.

**Interplay between complement and thrombosis in other thrombotic diseases**

HUS and aHUS are not the only diseases in which thrombosis and imbalance between complement activation and regulation are seen. Accordingly, it may be relevant for clinical hematologists to have an insight into the role of complement in these diseases as well. In each of the indicated diseases or conditions, endothelium, red cells, or platelets are damaged. This may contribute to coagulation and thrombosis, and direct procoagulative effects may also participate (red arrows). Thrombosis can lead to further tissue damage and increasing complement activation. The process can enhance itself via positive feedback loops and form a vicious cycle. Although complement is involved in each of these diseases, its impact needs to be clarified in clinical studies. CAPS, catastrophic antiphospholipid syndrome, DIC, disseminated intravascular coagulation; PLG, plasminogen; THBD, thrombomodulin.

**Conclusions**

Complement activation is central in the pathogenesis of aHUS. Complement activation may also contribute to pathogenesis in some patients with STEC-HUS and secondary HUS, either by regulation defects or by triggers that lead to enhanced complement activation. STEC-HUS is associated with a gastrointestinal infection with STEC, and secondary HUS is associated with a coexisting disease, whereas aHUS is usually associated with complement dysregulation leading to attack against all cells in contact with plasma. The typical clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage can be explained in STEC-HUS by the cytotoxic effects of Shiga toxin and in secondary HUS and aHUS usually by complement-mediated processes.

It is logical that therapeutic complement inhibition is effective in aHUS. The impact of complement in the pathogenesis of STEC-HUS and secondary HUS is still uncertain. Nevertheless, at least some patients seem to benefit from therapeutic complement inhibition, indicating that complement may also be involved in these diseases.

In the pathogenesis of aHUS, STEC-HUS, and at least some forms of secondary HUS, the interplay between complement, coagulation, and platelets seems to be essential. The primary point of process initiation could be either complement-mediated or not. Independent of the initiation point, the process may have similar features because of numerous feedback loops and powerful amplification under certain conditions. In general, it is likely that HUS and aHUS are not the only diseases in which the feedback loop among cell damage, coagulation and thrombosis, hypoxia-mediated endothelial activation, and activation of cells, platelets, and red cells, formation of fibrin or platelet thrombi (or both), tissue hypoxia as a result of vascular occlusion, further tissue damage, and damage-induced secondary complement overactivation (Figure 5). Most of the links in this kind of self-amplifying process are evident, but the clinical importance of some others in human diseases remains to be shown. The use of therapeutic complement inhibition beyond the current indications of eculizumab (aHUS and PNH) might demonstrate the relevance of complement in at least some of these disease processes.

---

*Note: Figure 5: Schematic model of the role of complement activation, cell damage, and thrombosis in various severe diseases or conditions with major thrombotic problems. Activation of complement can occur via the alternative pathway (in the absence of antibodies) or the classical pathway (in the presence of target-bound antibodies). In each of the indicated diseases or conditions, endothelium, red cells, or platelets are damaged. This may contribute to coagulation and thrombosis, and direct procoagulative effects may also participate (red arrows). Thrombosis can lead to further tissue damage and increasing complement activation. The process can enhance itself via positive feedback loops and form a vicious cycle. Although complement is involved in each of these diseases, its impact needs to be clarified in clinical studies. CAPS, catastrophic antiphospholipid syndrome, DIC, disseminated intravascular coagulation; PLG, plasminogen; THBD, thrombomodulin.*
of complement form a vicious cycle. Therefore, therapeutic complement inhibition may prove to be beneficial for a number of systemic thrombotic diseases in the future.

**Acknowledgments**

The author acknowledges Derek Ho, a postdoctoral fellow in the Jokiranta Research Group at the University of Helsinki, for proofreading the manuscript and Satu Hyvärinen for fruitful discussions on the pathogenesis of atypical hemolytic uremic syndrome.

Conflict-of-interest disclosure: T.S.J. has received lecture honoraria or consultation fees from AbbVie, Alexion Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Medac Pharma, Merck Sharp & Dohme, Pfizer, Roche, and Takeda Pharmaceuticals.

Correspondence: T. Sakari Jokiranta, Research Programs Unit, Immunobiology, Haartmaninkatu 3, FIN-00014, University of Helsinki, Helsinki, Finland; e-mail: sakari.jokiranta@helsinki.fi.

**References**


HUS and atypical HUS

T. Sakari Jokiranta